Beranda › Kanker Paru Non-Sel Kecil › Oregon › Gresham
Uji klinis Kanker Paru Non-Sel Kecil di Gresham, OR
4 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Gresham (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Menerima pesertaFase 2
- Clackamas Radiation Oncology Center, Clackamas · 9 mi jauhnya
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Menerima pesertaFase 3
- Northwest Cancer Specialists, P.C., Happy Valley · 6 mi jauhnya
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Menerima pesertaFase 3
- OHSU Knight Cancer Institute, Gresham, Gresham
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Northwest Cancer Specialists, P.C, Happy Valley · 6 mi jauhnya
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY120 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH56 studi
- Washington, DC55 studi
Studi lain di Gresham
- Kanker Prostat5 studi
- Kanker Kolorektal5 studi
- Kanker Mulut3 studi
- Kanker Paru3 studi
- Kanker Payudara3 studi
- Melanoma3 studi
- Kanker Kolon3 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.